About this source
- Kind
- Regulatory or official document
- Population
- Not applicable (UK-wide Yellow Card adverse-reaction reporting data)
- Sample size
- 13 ADR reports, 2011-2021
- Primary or secondary
- primary
- Peer review
- unknown
- Retraction status
- None known
- Date checked
- 14 August 2026
Limitations
The MHRA's own letter states Yellow Card inclusion does not establish causation and the scheme has an unknown, variable degree of under-reporting; the 13-report figure should not be read as true incidence.
Cited in
MHRA Yellow Card reports
Melanotan II · Safety finding
UK regulatory status
Melanotan II · UK regulatory status
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.